Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis.

Chun SH, Lee JE, Park MH, Kang JH, Kim YK, Wang YP, Park JK, Kim HK.

Cancer Res Treat. 2011 Dec;43(4):217-24. doi: 10.4143/crt.2011.43.4.217. Epub 2011 Dec 27.

2.

Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study.

Yuh YJ, Lee HR, Kim SR.

Cancer Res Treat. 2008 Sep;40(3):116-20. doi: 10.4143/crt.2008.40.3.116. Epub 2008 Sep 30.

3.

[Treatment of the unresectable non small cell lung carcinoma].

Spásová I.

Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3. Review. Czech.

PMID:
16193938
4.

A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.

Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS.

Lung Cancer. 2010 May;68(2):248-52. doi: 10.1016/j.lungcan.2009.06.026. Epub 2009 Aug 3.

PMID:
19647333
6.

[Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].

Langer F, Helsberg K, Schütte WH, Leschinger MI.

Onkologie. 2005 Mar;28 Suppl 1:1-28. Epub 2005 Mar 30. Review. German.

PMID:
15802886
7.

A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.

Park JS, Lee CM, Lee SA, Jung CK, Kim SH, Kwon HC, Kim JS, Kim HJ.

Cancer Res Treat. 2004 Feb;36(1):62-7. doi: 10.4143/crt.2004.36.1.62. Epub 2004 Feb 29.

8.

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.

Zhang GZ, Jiao SC, Meng ZT.

J Exp Clin Cancer Res. 2010 Apr 27;29:38. doi: 10.1186/1756-9966-29-38.

9.

Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

Gridelli C, Cigolari S, Maiorino A, Ianniello GP, Brancaccio L, Rossi A, De Cataldis G, Pedicini T, Maiorino L, Barletta E, Di Lanno M, Bilancia D, Crispino C, Barzelloni ML, Masullo P, D'Aniello R, Manzione L.

Lung Cancer. 2000 Jun;28(3):237-44.

PMID:
10812192
10.

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.

Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, et al.

J Natl Cancer Inst. 1995 Feb 1;87(3):198-205.

PMID:
7707407
11.
12.

Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.

Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P.

J Thorac Oncol. 2008 Sep;3(9):994-1002. doi: 10.1097/JTO.0b013e31818396cb.

PMID:
18758302
13.

Chemotherapy in Patients Older than or Equal to 75 Years with Advanced Non-small Cell Lung Cancer.

Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Kim YH, Shin SW.

Cancer Res Treat. 2012 Mar;44(1):37-42. doi: 10.4143/crt.2012.44.1.37. Epub 2012 Mar 31.

14.
15.

Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.

Ramsden K, Laskin J, Ho C.

Clin Oncol (R Coll Radiol). 2015 Jul;27(7):394-400. doi: 10.1016/j.clon.2015.03.001. Epub 2015 Mar 19.

PMID:
25800720
16.

The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer.

Karim NA, Bui H, Pathrose P, Starnes S, Patil N, Shehata M, Mostafa A, Rao M, Zarzour A, Anderson M.

Clin Med Insights Oncol. 2014 Dec 7;8:139-44. doi: 10.4137/CMO.S18369. eCollection 2014.

17.

A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.

Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Kim ST.

Am J Ther. 2015 Jan 29. [Epub ahead of print]

PMID:
25285672
18.

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets.

Alexa T, Lavinia A, Luca A, Miron L, Alexa ID.

Contemp Oncol (Pozn). 2014;18(5):340-3. doi: 10.5114/wo.2014.45293. Epub 2014 Nov 5.

19.

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.

Liu D, Wu C, Jiao Y, Hou L, Lu D, Zheng H, Chen C, Qian J, Fei K, Su B.

Sci Rep. 2015 Jun 9;5:11114. doi: 10.1038/srep11114.

20.

Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma.

Li CT, Marek M, Guclu SZ, Kim Y, Meshref M, Qin S, Kadziola Z, Krejcy K, Altug S.

J Cancer. 2011 Jan 11;2:52-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk